RT Journal Article SR Electronic T1 Mycoplasma genitalium in Toronto, Ont JF Canadian Family Physician JO Can Fam Physician FD The College of Family Physicians of Canada SP e96 OP e101 VO 62 IS 2 A1 Dionne Gesink A1 C. Sarai Racey A1 Christine Seah A1 Sandra Zittermann A1 Leo Mitterni A1 Jerry Juzkiw A1 Heather Jamieson A1 Jane Greer A1 Sudesh Singh A1 Jørgen Skov Jensen A1 Vanessa Allen YR 2016 UL http://www.cfp.ca/content/62/2/e96.abstract AB Objective To estimate the prevalence of Mycoplasma genitalium in Toronto, Ont; detect mutations associated with macrolide and fluoroquinolone resistance; and describe treatment outcomes.Design Prospective, cross-sectional study.Setting A sexual health clinic in Toronto.Participants A consecutive sample of men and women attending the sexual health clinic between September 1, 2013, and December 20, 2013.Interventions Participants underwent testing for M genitalium, along with standard sexually transmitted infection screening. All samples that had positive results for M genitalium were tested for mutations associated with resistance to macrolides and fluoroquinolones. Mycoplasma genitalium treatment was based on resistance profile and verified with a test of cure.Main outcome measures Positive results for M genitalium and antibiotic resistance.Results A total of 1193 men and women participated in the study. Overall, 4.5% of the 884 men and 3.2% of the 309 women had positive test results for M genitalium. Asymptomatic infection was common (52.0%). Macrolide resistance–mediating mutations were found in 58.0% of the M genitalium infections. No treatment failure was observed for azithromycin-treated cases. Treatment failure was suspected for 16.7% of cases treated with moxifloxacin.Conclusion Mycoplasma genitalium is present in Canada, with a prevalence comparable to chlamydia and gonorrhea, and has high macrolide and fluoroquinolone resistance.